Background: Despite the lack of replication of the NINDS & ECASS-3 trials, guidelines recommend the use of tPA in the ≤4.5hr window after the onset of symptoms of acute ischemic stroke [2]. These recommendations used non-contrast computed tomography (NCHCT) for the …
The shiny new toy in stroke treatment is endovascular therapy. There have now been 12 randomized controlled trials (RCTs) on endovascular stroke therapy (EST), with eight of the last nine showing positive results – stunningly positive. This flood of positive …
Background: No matter which side of the debate you sit on in regard to systemic thrombolysis in acute ischemic stroke (AIS), there is one truth: systems have undergone major changes to ensure tPA is offered to patients in the ≤4.5-hour window. …
Background: Despite serious concerns about the role of alteplase in the management of acute ischemic stroke including, but not limited to, significant conflicts of interest, unbalanced baseline patient characteristics, systematic devaluation of contrary data, lack of reproduced benefit and low …
With the publication of the DAWN and DEFUSE-3 trials came a new era in stroke management. We have discussed the specific literature pertaining to endovascular therapy on REBEL EM before in our 2hour CME activity HERE. Along with the two new publications …
© 2022 REBEL EM. All rights reserved. | Disclaimer | Website by Innov8 Place.
